By Dean Seal
South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.
The Supreme Court of Korea has ruled that the individual conjugates comprising SK Bioscience's 13-valent pneumococcal conjugate vaccine, or PCV13, don't fall within the scope of Pfizer's patent claims, SK Bioscience said Wednesday.
The high court also confirmed that the production and supply of PCV13 finished products for research purposes don't constitute patent infringement, the company said.
A representative for Pfizer didn't immediately respond to a request for comment.
Pfizer claimed in its 2020 suit that SK Bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent for Prevnar 13, its pneumococcal vaccine.
Now that the ruling has come down, SK Bioscience said it intends to start exporting individual components of PCV13 to countries with high vaccine demand, including nations in Southeast Asia and Latin America.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 21, 2025 08:39 ET (12:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。